Overview

• Myriad Genetics Q3 2025 revenue declines 4% yr/yr, beats analyst expectations

• Adjusted operating income for Q3 beats analyst estimates

• Company recently entered into strategic collaboration with SOPHiA GENETICS for liquid biopsy CDx testing

Outlook

• Myriad Genetics reaffirms full-year 2025 revenue guidance of $818 mln to $828 mln

• Gross margin for 2025 expected between 69.5% and 70.0%

• Adjusted EPS for 2025 projected between $(0.02) and $0.02

Result Drivers

• HEREDITARY CANCER GROWTH - Hereditary cancer testing revenue and volume grew 3% and 11% yr/yr, respectively

• STRATEGIC COLLABORATION - Entered collaboration with SOPHiA GENETICS to develop liquid biopsy CDx testing solution

• PHARMACOGENOMICS DECLINE - Revenue impacted by UnitedHealthcare's discontinuation of coverage for GeneSight

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 8 "hold" and 3 "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

• Wall Street's median 12-month price target for Myriad Genetics Inc is $6.50, about 23.7% below its October 31 closing price of $8.04

• The stock recently traded at 99 times the next 12-month earnings vs. a P/E of 51 three months ago

Press Release: ID:nGNXbqW5TY

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)